Healio

FDA approves Ingrezza sprinkle capsules for tardive dyskinesia, Huntington’s chorea

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive ...
Nasdaq

FDA Approves Neurocrine Biosciences' INGREZZA Sprinkle Capsules

(RTTNews) - The U.S. Food and Drug Administration has approved INGREZZA Sprinkle (valbenazine) capsules, a new oral granules formulation of INGREZZA (valbenazine) capsules prescribed for the treatment ...
Monthly Prescribing Reference

FDA Approves New Ingrezza Formulation for Patients Who Have Difficulty Swallowing

Ingrezza Sprinkle capsules can be opened and sprinkled over a bowl containing a small amount of soft food. The Food and Drug Administration (FDA) has approved Ingrezza ® Sprinkle (valbenazine) for the ...
Seeking Alpha

Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules

SAN DIEGO, April 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA ® SPRINKLE (valbenazine) ...
Monthly Prescribing Reference

Sprinkle Formulation of Ingrezza Now Available

Ingrezza Sprinkle is available in the 3 dosage strengths: 40mg, 60mg, and 80mg. Ingrezza ® Sprinkle (valbenazine) is now available for the treatment of adults with tardive dyskinesia and chorea ...
The Daily Astorian

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically ...

“Tardive dyskinesia can significantly impact many aspects of patients’ lives, including daily activities, work or school attendance and social interactions,” said Eiry W. Roberts, M.D., Chief Medical ...
La Grande Observer

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder Findings Presented at the 2025 Psychiatry Update Conference ...
Seeking Alpha

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive ...

SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) presented data from the long-term KINECT ®-4 study demonstrating tardive dyskinesia remission in nearly 60% ...
Healio

FDA accepts new drug application for sprinkle form of Ingrezza capsules

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Morningstar

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia

SAN DIEGO, May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study (NCT03891862) showing ...
Morningstar

Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing ...

The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from ...
La Grande Observer

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically ...

SAN DIEGO, Feb. 27, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustained ...